Skip to main content
Top
Published in: Current Allergy and Asthma Reports 3/2011

01-06-2011

Guillain-Barré Syndrome: Modern Theories of Etiology

Authors: Todd A. Hardy, Stefan Blum, Pamela A. McCombe, Stephen W. Reddel

Published in: Current Allergy and Asthma Reports | Issue 3/2011

Login to get access

Abstract

Guillain-Barré syndrome (GBS) is a classic failure of the immune system with a life-threatening attack upon a critical self-component. The active phase of the disease is short, concordant with the latency of a primary adaptive immune response. Triggers for GBS include infection and (rarely) vaccination; cross-reactivity between infectious and neural epitopes has been well demonstrated, particularly for Campylobacter jejuni and motor axonal forms of GBS in which non-protein gangliosides are antigenic. Most people are probably exposed to a GBS trigger, but only rarely does the disease develop. We propose that GBS illustrates competing determinants of the immune system’s decision about whether to mount a response, and that in unlucky affected individuals, co-presentation of cross-reactive antigens with danger signals activating pattern-recognition receptors overcomes normal self-recognition such that a primary response is initiated that attacks the nerve. Then, in most cases of GBS, the response rapidly turns off, and second attacks rarely occur. This suggests active restoration of tolerance, and specific privileged site attributes of nerve and declining danger signals as the trigger wanes may contribute to this restoration. Standard immunosuppression has not been effective in GBS. We suggest this is because immune tolerance is already being restored by the time such therapies are initiated. This in turn suggests that improvements in GBS outcomes are likely to come from better protection of the nerve cells under attack while normal resumption of tolerance is permitted to proceed rather than exploring more aggressive immunosuppressive approaches.
Literature
1.
2.
go back to reference Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70:1608–13.PubMedCrossRef Alshekhlee A, Hussain Z, Sultan B, Katirji B. Guillain-Barre syndrome: incidence and mortality rates in US hospitals. Neurology. 2008;70:1608–13.PubMedCrossRef
3.
go back to reference van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–50.PubMedCrossRef van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol. 2008;7:939–50.PubMedCrossRef
5.
go back to reference Ruts L, Drenthen J, Jacobs BC, Van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74:1680–6.PubMedCrossRef Ruts L, Drenthen J, Jacobs BC, Van Doorn PA. Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study. Neurology. 2010;74:1680–6.PubMedCrossRef
6.
go back to reference Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110:105–23.PubMed Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976–1977. Am J Epidemiol. 1979;110:105–23.PubMed
7.
go back to reference Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 1998;339:1797–802.PubMedCrossRef Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barre syndrome and the 1992–1993 and 1993–1994 influenza vaccines. N Engl J Med. 1998;339:1797–802.PubMedCrossRef
9.
go back to reference Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barre syndrome. Drug Saf. 2009;32:309–23.PubMedCrossRef Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barre syndrome. Drug Saf. 2009;32:309–23.PubMedCrossRef
10.
go back to reference Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Medicine. 1969;48:173–215.PubMedCrossRef Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Medicine. 1969;48:173–215.PubMedCrossRef
11.
go back to reference Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve. 2004;30:131–56.PubMedCrossRef Kieseier BC, Kiefer R, Gold R, et al. Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve. 2004;30:131–56.PubMedCrossRef
12.
go back to reference Csurhes PA, Sullivan AA, Green K, et al. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2005;76:1431–9.PubMedCrossRef Csurhes PA, Sullivan AA, Green K, et al. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry. 2005;76:1431–9.PubMedCrossRef
13.
go back to reference McCombe PA, Csurhes PA. T cells from patients with Guillain-Barre syndrome produce interferon-gamma in response to stimulation with the ganglioside GM1. J Clin Neurosci. 2010;17:537–8.PubMedCrossRef McCombe PA, Csurhes PA. T cells from patients with Guillain-Barre syndrome produce interferon-gamma in response to stimulation with the ganglioside GM1. J Clin Neurosci. 2010;17:537–8.PubMedCrossRef
14.
go back to reference Chi L-J, Wang H-B, Zhang Y, Wang W-Z. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol. 2007;192:206–14.PubMedCrossRef Chi L-J, Wang H-B, Zhang Y, Wang W-Z. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barre syndrome. J Neuroimmunol. 2007;192:206–14.PubMedCrossRef
15.
go back to reference Harness J, McCombe PA. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci. 2008;15:1031–5.PubMedCrossRef Harness J, McCombe PA. Increased levels of activated T-cells and reduced levels of CD4/CD25+ cells in peripheral blood of Guillain-Barré syndrome patients compared to controls. J Clin Neurosci. 2008;15:1031–5.PubMedCrossRef
16.
go back to reference Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–35.PubMedCrossRef Hafer-Macko CE, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol. 1996;39:625–35.PubMedCrossRef
17.
go back to reference Inglis HR, Csurhes PA, McCombe PA. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry. 2007;78:419–22.PubMedCrossRef Inglis HR, Csurhes PA, McCombe PA. Antibody responses to peptides of peripheral nerve myelin proteins P0 and P2 in patients with inflammatory demyelinating neuropathy. J Neurol Neurosurg Psychiatry. 2007;78:419–22.PubMedCrossRef
18.
go back to reference Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986;109:1115–26.PubMedCrossRef Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barre polyneuropathy. Brain. 1986;109:1115–26.PubMedCrossRef
19.
go back to reference McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33:333–42.PubMedCrossRef McKhann GM, Cornblath DR, Griffin JW, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol. 1993;33:333–42.PubMedCrossRef
20.
go back to reference Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol. 1996;39:17–28.PubMedCrossRef Griffin JW, Li CY, Ho TW, et al. Pathology of the motor-sensory axonal Guillain-Barre syndrome. Ann Neurol. 1996;39:17–28.PubMedCrossRef
21.
go back to reference Ang CW, Yuki N, Jacobs BC, et al. Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies. Neurology. 1999;53:2122–7.PubMed Ang CW, Yuki N, Jacobs BC, et al. Rapidly progressive, predominantly motor Guillain-Barre syndrome with anti-GalNAc-GD1a antibodies. Neurology. 1999;53:2122–7.PubMed
22.
go back to reference Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol. 1999;45:168–73.PubMedCrossRef Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol. 1999;45:168–73.PubMedCrossRef
23.
go back to reference Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49:712–20.PubMedCrossRef Yuki N, Yamada M, Koga M, et al. Animal model of axonal Guillain-Barre syndrome induced by sensitization with GM1 ganglioside. Ann Neurol. 2001;49:712–20.PubMedCrossRef
24.
go back to reference Lopez PHH, Zhang G, Bianchet MA, et al. Structural requirements of anti-GD1a antibodies determine their target specificity. Brain. 2008;131:1926–39.PubMedCrossRef Lopez PHH, Zhang G, Bianchet MA, et al. Structural requirements of anti-GD1a antibodies determine their target specificity. Brain. 2008;131:1926–39.PubMedCrossRef
25.
go back to reference Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome: Mini-review. J Neuroimmunol. 2010;223:5–12.PubMedCrossRef Kaida K, Kusunoki S. Antibodies to gangliosides and ganglioside complexes in Guillain-Barre syndrome and Fisher syndrome: Mini-review. J Neuroimmunol. 2010;223:5–12.PubMedCrossRef
26.
go back to reference Rinaldi S, Willison HJ. Ganglioside antibodies and neuropathies. Curr Opin Neurol. 2008;21:540–6.PubMedCrossRef Rinaldi S, Willison HJ. Ganglioside antibodies and neuropathies. Curr Opin Neurol. 2008;21:540–6.PubMedCrossRef
27.
go back to reference Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40:635–44.PubMedCrossRef Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol. 1996;40:635–44.PubMedCrossRef
28.
go back to reference • Halstead SK, Zitman FMP, Humphreys PD, et al: Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008, 131:1197–1208. This study demonstrated a realistic therapy for possible trials in human GBS. PubMedCrossRef • Halstead SK, Zitman FMP, Humphreys PD, et al: Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008, 131:1197–1208. This study demonstrated a realistic therapy for possible trials in human GBS. PubMedCrossRef
29.
go back to reference Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci. 1999;168:121–6.PubMedCrossRef Yuki N, Kuwabara S, Koga M, Hirata K. Acute motor axonal neuropathy and acute motor-sensory axonal neuropathy share a common immunological profile. J Neurol Sci. 1999;168:121–6.PubMedCrossRef
30.
go back to reference Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry. 2010;81:1157–63.PubMedCrossRef Uncini A, Manzoli C, Notturno F, Capasso M. Pitfalls in electrodiagnosis of Guillain-Barré syndrome subtypes. J Neurol Neurosurg Psychiatry. 2010;81:1157–63.PubMedCrossRef
31.
go back to reference Madrid RE, Wiśniewski HM. Axonal degeneration in demyelinating disorders. J Neurocytol. 1977;6:103–17.PubMedCrossRef Madrid RE, Wiśniewski HM. Axonal degeneration in demyelinating disorders. J Neurocytol. 1977;6:103–17.PubMedCrossRef
32.
go back to reference Sobottka B, Harrer MD, Ziegler U, et al. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am J Pathol. 2009;175:1160–6.PubMedCrossRef Sobottka B, Harrer MD, Ziegler U, et al. Collateral bystander damage by myelin-directed CD8+ T cells causes axonal loss. Am J Pathol. 2009;175:1160–6.PubMedCrossRef
33.
go back to reference Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31:677–9.PubMedCrossRef Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann Neurol. 1992;31:677–9.PubMedCrossRef
34.
go back to reference Damian RT. Molecular mimicry: antigen sharing by parasite and host and its consequences. Am Nat. 1964;98:129–49.CrossRef Damian RT. Molecular mimicry: antigen sharing by parasite and host and its consequences. Am Nat. 1964;98:129–49.CrossRef
35.
go back to reference Yuki N, Kuwabara S. Axonal Guillain-Barre syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst. 2007;12:238–49.PubMedCrossRef Yuki N, Kuwabara S. Axonal Guillain-Barre syndrome: carbohydrate mimicry and pathophysiology. J Peripher Nerv Syst. 2007;12:238–49.PubMedCrossRef
36.
go back to reference van Belkum A, van den Braak N, Godschalk P, et al. A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat Med. 2001;7:752–3.PubMedCrossRef van Belkum A, van den Braak N, Godschalk P, et al. A Campylobacter jejuni gene associated with immune-mediated neuropathy. Nat Med. 2001;7:752–3.PubMedCrossRef
37.
go back to reference Koga M, Takahashi M, Masuda M, et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barre syndrome. Neurology. 2005;65:1376–81.PubMedCrossRef Koga M, Takahashi M, Masuda M, et al. Campylobacter gene polymorphism as a determinant of clinical features of Guillain-Barre syndrome. Neurology. 2005;65:1376–81.PubMedCrossRef
38.
go back to reference Halstead SK, O’Hanlon GM, Humphreys PD, et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain. 2004;127:2109–23.PubMedCrossRef Halstead SK, O’Hanlon GM, Humphreys PD, et al. Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy. Brain. 2004;127:2109–23.PubMedCrossRef
39.
go back to reference Illa I, Ortiz N, Gallard E, et al. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol. 1995;38:218–24.PubMedCrossRef Illa I, Ortiz N, Gallard E, et al. Acute axonal Guillain-Barre syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol. 1995;38:218–24.PubMedCrossRef
40.
go back to reference Shamshiev A, Donda A, Prigozy TI, et al. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity. 2000;13:255–64.PubMedCrossRef Shamshiev A, Donda A, Prigozy TI, et al. The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity. 2000;13:255–64.PubMedCrossRef
41.
go back to reference Shamshiev A, Donda A, Carena I, et al. Self glycolipids as T-cell autoantigens. Eur J Immunol. 1999;29:1667–75.PubMedCrossRef Shamshiev A, Donda A, Carena I, et al. Self glycolipids as T-cell autoantigens. Eur J Immunol. 1999;29:1667–75.PubMedCrossRef
42.
go back to reference Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Investig. 2004;114:1379–88.PubMed Godfrey DI, Kronenberg M. Going both ways: immune regulation via CD1d-dependent NKT cells. J Clin Investig. 2004;114:1379–88.PubMed
43.
go back to reference Spies JM, Westland KW, Bonner JG, Pollard JD. Intraneural activated T cells cause focal breakdown of the blood–nerve barrier. Brain. 1995;118:857–68.PubMedCrossRef Spies JM, Westland KW, Bonner JG, Pollard JD. Intraneural activated T cells cause focal breakdown of the blood–nerve barrier. Brain. 1995;118:857–68.PubMedCrossRef
44.
go back to reference Pollard JD, Westland KW, Harvey GK, et al. Activated T cells of nonneural specificity open the blood–nerve barrier to circulating antibody. Ann Neurol. 1995;37:467–75.PubMedCrossRef Pollard JD, Westland KW, Harvey GK, et al. Activated T cells of nonneural specificity open the blood–nerve barrier to circulating antibody. Ann Neurol. 1995;37:467–75.PubMedCrossRef
45.
go back to reference Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118:597–605.PubMedCrossRef Ho TW, Mishu B, Li CY, et al. Guillain-Barre syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain. 1995;118:597–605.PubMedCrossRef
46.
go back to reference • Kuitwaard K, van Koningsveld R, Ruts L, et al: Recurrent Guillain Barre syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2009, 80:56–59. This article confirmed the low rate of recurrent GBS and demonstrated that the few patients who do have recurrences have other features of autoimmunity, and that the standard on-off case does not. CrossRef • Kuitwaard K, van Koningsveld R, Ruts L, et al: Recurrent Guillain Barre syndrome. Journal of Neurology, Neurosurgery & Psychiatry 2009, 80:56–59. This article confirmed the low rate of recurrent GBS and demonstrated that the few patients who do have recurrences have other features of autoimmunity, and that the standard on-off case does not. CrossRef
47.
go back to reference • Steiner I, Rosenberg G, Wirguin I: Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barre syndrome? Clin Exp Immunol 2010. This article presents an interesting related hypothesis that suggests more of a role for transient immunosuppression as an initiating feature but also deals well with the reasons why GBS is not a typical autoimmune disease. • Steiner I, Rosenberg G, Wirguin I: Transient immunosuppression: a bridge between infection and the atypical autoimmunity of Guillain-Barre syndrome? Clin Exp Immunol 2010. This article presents an interesting related hypothesis that suggests more of a role for transient immunosuppression as an initiating feature but also deals well with the reasons why GBS is not a typical autoimmune disease.
48.
Metadata
Title
Guillain-Barré Syndrome: Modern Theories of Etiology
Authors
Todd A. Hardy
Stefan Blum
Pamela A. McCombe
Stephen W. Reddel
Publication date
01-06-2011
Publisher
Current Science Inc.
Published in
Current Allergy and Asthma Reports / Issue 3/2011
Print ISSN: 1529-7322
Electronic ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-011-0190-y

Other articles of this Issue 3/2011

Current Allergy and Asthma Reports 3/2011 Go to the issue